Jakarta (VNA) - Indonesia’s National Research and Innovation Agency(BRIN) plans to initiate the development of a homegrown dengue hemorrhagicfever (DBD) vaccine.
As reported by the national news agency Antara, Doddy IrawanSetyo Utomo, a vaccine development researcher at the vaccine and drug researchcentre of BRIN’s Health Research Organisation, said the vaccine development isplanned to use the virus-like particle (VLP) method that can trigger theformation of antibodies.
Utomo said the method used for developing the dengue vaccinein Indonesia is different from Dengvaxia and Qdenga, which have already been in circulationand use virus weakening methods.
According to him, through the VLP method, the effectivenessof the vaccine developed by Indonesia can reach 90-95%.
Utomo said the development process itself can take 5-10years, because it must go through clinical trials, safety, regulatory approval,and a mass production process./.
As reported by the national news agency Antara, Doddy IrawanSetyo Utomo, a vaccine development researcher at the vaccine and drug researchcentre of BRIN’s Health Research Organisation, said the vaccine development isplanned to use the virus-like particle (VLP) method that can trigger theformation of antibodies.
Utomo said the method used for developing the dengue vaccinein Indonesia is different from Dengvaxia and Qdenga, which have already been in circulationand use virus weakening methods.
According to him, through the VLP method, the effectivenessof the vaccine developed by Indonesia can reach 90-95%.
Utomo said the development process itself can take 5-10years, because it must go through clinical trials, safety, regulatory approval,and a mass production process./.
VNA
